Skip to content

IAS: Rifampin TB treatment does not reduce response to NNRTIs, South Africans report

Rifampicin resistance linked to dosing schedule in HIV-positive TB patients

BHIVA audit gives a good report on management of HIV/TB patients, but areas of concern highlighted

Study in southern Mexico reports that DOTS programme can reduce the prevalence of drug resistant TB

TB drug discovery to receive major boost

Report suggests short course of rifampicin/isoniazid as effective as standard course of isoniazid for the treatment of latent TB

Six- and nine-month courses of TB treatment equivalent in Indian HIV-positive patients

Roche issues warning about use of boosted saquinavir with rifampicin

Cotrimoxazole prophylaxis reduces the risk of death in TB patients